REmote SUpervision to Decrease HospitaLization RaTe. Unified and integrated platform for data collected from devices manufactured by different companies: Design and rationale of the RESULT study
Mateusz Tajstra, Adam Sokal, Arkadiusz Gwóźdź, Marcin Wilczek, Adam Gacek, Konrad Wojciechowski, Elżbieta Gadula-Gacek, Elżbieta Adamowicz-Czoch, Katarzyna Chłosta-Niepiekło, Krzysztof Milewski, Piotr Rozentryt, Zbigniew Kalarus, Mariusz Gąsior, Lech Poloński, Mateusz Tajstra, Adam Sokal, Arkadiusz Gwóźdź, Marcin Wilczek, Adam Gacek, Konrad Wojciechowski, Elżbieta Gadula-Gacek, Elżbieta Adamowicz-Czoch, Katarzyna Chłosta-Niepiekło, Krzysztof Milewski, Piotr Rozentryt, Zbigniew Kalarus, Mariusz Gąsior, Lech Poloński
Abstract
The number of patients with heart failure implantable cardiac electronic devices (CIEDs) is growing. Hospitalization rate in this group is very high and generates enormous costs. To avoid the need for hospital treatment, optimized monitoring and follow-up is crucial. Remote monitoring (RM) has been widely put into practice in the management of CIEDs but it may be difficult due to the presence of differences in systems provided by device manufacturers and loss of gathered data in case of device reimplantation. Additionally, conclusions derived from studies about usefulness of RM in clinical practice apply to devices coming only from a single company. An integrated monitoring platform allows for more comprehensive data analysis and interpretation. Therefore, the primary objective of Remote Supervision to Decrease Hospitalization Rate (RESULT) study is to evaluate the impact of RM on the clinical status of patients with ICDs or CRT-Ds using an integrated platform. Six hundred consecutive patients with ICDs or CRT-Ds implanted will be prospectively randomized to either a traditional or RM-based follow-up model. The primary clinical endpoint will be a composite of all-cause mortality or hospitalization for cardiovascular reasons within 12 months after randomization. The primary technical endpoint will be to construct and evaluate a unified and integrated platform for the data collected from RM devices manufactured by different companies. This manuscript describes the design and methodology of the prospective, randomized trial designed to determine whether remote monitoring using an integrated platform for different companies is safe, feasible, and efficacious (ClinicalTrials.gov Identifier: NCT02409225).
Keywords: RESULT study; heart failure; integrated platform; remote monitoring.
Conflict of interest statement
None declared.
© 2016 Wiley Periodicals, Inc.
Figures



Source: PubMed
다가오는 임상 시험
-
Aperta Biosciences, LLC아직 모집하지 않음
-
Hospices Civils de Lyon아직 모집하지 않음요실금 | 신경성 방광 | 요로 전환 | 골반 악성종양 | 방광암프랑스
-
Second Affiliated Hospital, Zhejiang University...모병정상적인 청력 | 소음 노출 | Preferred Loudness Level중국
-
Qilu Pharmaceutical Co., Ltd.아직 모집하지 않음투명 세포 신장 세포 암종 | 난소 암 | 기타 진행성 고형 종양중국
-
University Hospital, Antwerp아직 모집하지 않음신생아의 괴사성 소장결장염 | 후기 발병 신생아 패혈증벨기에, 네덜란드
-
VA Office of Research and Development아직 모집하지 않음전이성 비소세포폐암 | Cancer-Associated Weight Loss | Elevated Inflammatory Markers미국
-
ENTire Medical Ltd.아직 모집하지 않음비대 | 편도선 절제술 | 기도 폐쇄 갑피 | 아데노이드절제술미국
-
AbbVie아직 모집하지 않음
-
Institute of Hematology & Blood Diseases Hospital...모병
-
Ahmed Nasser Ali Mabkhout모병턱 낭종 | Alveolar Bone Defects예멘
-
University of Coimbra아직 모집하지 않음